Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Relapsing-Remitting Multiple Sclerosis (RRMS)”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)UnknownNCT01466114
What this trial is testing

Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition

Who this might be right for
Relapsing-remitting Multiple SclerosisSecondary-progressive Multiple SclerosisPrimary-progressive Multiple Sclerosis
University of California, Los Angeles 64
Large-scale testing (Phase 3)UnknownNCT01333358
What this trial is testing

Evaluating Alemtuzumab as a Treatment in Stabilizing Neurocognitive Function In Relapsing Remitting Multiple Sclerosis Patients

Who this might be right for
Multiple Sclerosis
Central Texas Neurology Consultants 30
Not applicableStudy completedNCT03408093
What this trial is testing

Study of Betaferon Adherence in Patients With Multiple Sclerosis Treated With Interferon Beta-1b

Who this might be right for
Multiple Sclerosis
Bayer 120
Large-scale testing (Phase 3)Study completedNCT01307332
What this trial is testing

Advanced MRI Measures of Repair in Alemtuzumab Treated Patients

Who this might be right for
Relapsing Remitting Multiple Sclerosis
University of British Columbia 27
Testing effectiveness (Phase 2)Study completedNCT01116427
What this trial is testing

A Cooperative Clinical Study of Abatacept in Multiple Sclerosis

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
National Institute of Allergy and Infectious Diseases (NIAID) 65
Large-scale testing (Phase 3)Looking for participantsNCT07189325
What this trial is testing

A Prospective Randomized Non-inferiority Trial Comparing Anti-CD20 Maintenance Versus De-Escalation Strategy In Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing-Remitting Multiple Sclerosis (RRMS)Anti-CD20 Therapy
University Hospital, Montpellier 250
Not applicableStudy completedNCT01110993
What this trial is testing

An Observational Study to Evaluate Quality of Life (QoL) and Influence of Cognitive Status on QoL in Patients With Relapsing-Remitting Multiple Sclerosis (RRMS) During 2 Years Treatment With Rebif New Formulation (RNF)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Merck KGaA, Darmstadt, Germany 65
Not applicableNot Yet RecruitingNCT06949956
What this trial is testing

Administration of Fingolimod in Greek Patients With Multiple Sclerosis.

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Elpen Pharmaceutical Co. Inc. 140
Large-scale testing (Phase 3)Ended earlyNCT02881567
What this trial is testing

Efficacy and Safety of Daclizumab in Participants With RRMS Switching From Natalizumab

Who this might be right for
Relapsing-Remitting Multiple Sclerosis (RRMS)
Biogen 41
Post-approval studies (Phase 4)Study completedNCT01705236
What this trial is testing

A 3-year Multi-center Study to Describe Changes of OCT Parameters Under Treatment With Gilenya®

Who this might be right for
Relapsing Remitting Multiple Sclerosis RRMS
Novartis Pharmaceuticals 87
Large-scale testing (Phase 3)Looking for participantsNCT07321093
What this trial is testing

The Efficacy and Safety of BCD-281 in Patients With Relapsing-Remitting Multiple Sclerosis

Who this might be right for
Relapsing-remitting Multiple Sclerosis (RRMS)
Biocad 292
Not applicableLooking for participantsNCT07292480
What this trial is testing

Monthly Monitoring of Plasma NfL in Treated Relapsing-remitting Multiple Sclerosis to Detect Persistent Infraclinical Disease Activity

Who this might be right for
Multiple Sclerosis (MS) - Relapsing-remitting
Centre Hospitalier Universitaire de Nīmes 84
Not applicableStudy completedNCT00461396
What this trial is testing

Success of Titration, Analgesics, and B.E.T.A Nurse Support on Acceptance Rates in Early Multiple Sclerosis (MS) Treatment With Betaseron

Who this might be right for
Multiple SclerosisMultiple Sclerosis, Relapsing-Remitting
Bayer 104
Not applicableEnded earlyNCT02323269
What this trial is testing

Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)

Who this might be right for
Multiple Sclerosis, Relapsing-RemittingRelapsing-Remitting Multiple Sclerosis
Biogen 24
Not applicableStudy completedNCT02588053
What this trial is testing

Does Long-Term Natalizumab (NTZ) Therapy Normalize Brain Atrophy Rates and Quality of Life (QOL) in Relapsing Remitting Multiple Sclerosis (RRMS)?

Who this might be right for
Multiple Sclerosis
University of Colorado, Denver 85
Post-approval studies (Phase 4)Ended earlyNCT02342704
What this trial is testing

Impact of Natalizumab Versus Fingolimod in Relapsing-Remitting Multiple Sclerosis (RRMS) Participants

Who this might be right for
Relapsing-Remitting Multiple Sclerosis
Biogen 111
Testing effectiveness (Phase 2)Study completedNCT02212886
What this trial is testing

Safety, Tolerability and Efficacy of Monthly Long-acting IM Injection of 80 or 40 mg GA Depot in Subjects With RRMS

Who this might be right for
Multiple Sclerosis
Mapi Pharma Ltd. 25
Post-approval studies (Phase 4)Study completedNCT03177083
What this trial is testing

Evaluate Safety/Tolerability in Portuguese Participants With RRMS Transitioning From Current Therapy

Who this might be right for
Relapsing Remitting Multiple Sclerosis
Biogen 80
Early research (Phase 1)Study completedNCT01738347
What this trial is testing

Assess Safety, Bio-distribution, Radiation Dosimetry and Optimize the Imaging Protocol of GEH120714 (18F) Injection in Healthy Volunteers and Participants With Relapsing and Remitting Multiple Sclerosis (rrMS).

Who this might be right for
Relapsing-remitting Multiple Sclerosis (rrMS)
GE Healthcare 30
Large-scale testing (Phase 3)Study completedNCT02861014
What this trial is testing

Ocrelizumab in Participants With Relapsing Remitting Multiple Sclerosis (RRMS) Who Have Had a Suboptimal Response to an Adequate Course of Disease-Modifying Treatment (DMT)

Who this might be right for
Multiple Sclerosis, Relapsing-Remitting
Hoffmann-La Roche 681
Next Page